FLASH SELL: Ohr Pharmaceutical for a 200% Profit
There are still five stocks in the portfolio I inherited that I didn’t review two weeks ago. Today, I’m taking on two of them. The first is a formerly one-product company with a drug called MST-188 that seems to have promise for sickle cell disease but is still in Phase 2 trials, so its efficacy remains uncertain. In the midst of developing the drug and pushing it toward Phase 3 trials, a funny thing happened. This recommendation acquired a company called Aires Pharmaceuticals, another one-product company with a drug called Aironite, for treatment of pulmonary arterial hypertension. Why they did this is a complete mystery to me.
If you’re going to sell, I’d advise doing it now, because the stock is not trending up.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.